AI-driven drug discovery and aging · news_exa
AI-Driven Aging Digital Twins: A Roadmap for Clinical Translation in Precision Geriatrics
By news_exa · just now
TL;DR: Digital twins for aging patients provide a roadmap for personalized geriatric care.
The roadmap for 'Aging Digital Twins' offers a transformative approach to precision geriatrics. By creating virtual models of individual patients, AI can predict health outcomes and personalize treatments before they are applied. This paves the way for a highly individualized era of elderly care.
AI-driven drug discovery and aging · news_exa
York Daily Record - Home
By Distributed by EIN Presswire · 1d ago
TL;DR: Unicorn startup 600and1 launches an AI incubator focused on human longevity.
The biotech unicorn 600and1 has launched a new AI-powered incubator specifically targeted at longevity and the biological limits of aging. By combining venture capital with advanced machine learning, the incubator seeks to spawn the next generation of anti-aging startups. It’s a bold bet on the intersection of deep tech and human lifespan extension.
AI-driven drug discovery and aging · news_exa
Extreme age protects against cancer in Stanford University mouse study
By news_exa · 1d ago
TL;DR: Stanford study finds that extreme age may provide natural cancer protection.
A new study from Stanford University reveals a surprising biological phenomenon: extreme age appears to provide protection against cancer in mice. Researchers are investigating the mechanisms that allow the oldest subjects to resist tumor growth better than their slightly younger counterparts. These insights could lead to radical new strategies for cancer prevention in elderly humans.
AI-driven drug discovery and aging · news_exa
Home
By WELTCORP · 1d ago
TL;DR: WELT debuts the world's first AI-integrated combination drug at CES 2026.
WELT has introduced what it calls the world's first 'AI-Combo Drug' at CES 2026, marking a fusion of traditional pharmacology and digital health. This innovative approach seeks to enhance medication efficacy by integrating AI-driven monitoring and support. It signifies a major shift toward personalized, tech-enabled medicine for better patient outcomes.
AI-driven drug discovery and aging · news_exa
A comprehensive review of artificial intelligence as a catalyst in aging research: insights, gaps and future perspectives - PMC
By news_exa · just now
TL;DR: A high-level framework for how AI is accelerating modern aging and longevity research.
This comprehensive review explores how artificial intelligence serves as a critical catalyst in modern aging research. Researchers examine current insights and identify significant gaps in using AI to understand biological decline. The study provides a strategic roadmap for future perspectives in the quest to extend human healthspan.
AI-driven drug discovery and aging · news_exa
Study signals a first in drug discovery: AI can tackle aging's true complexity
By news_exa · just now
TL;DR: AI proves capable of deciphering the complex biological networks of aging.
A new study marks a milestone in drug discovery by proving AI can navigate the immense complexity of biological aging. By processing multi-dimensional data, the system identifies therapeutic targets that human researchers might overlook. This signals a shift toward more sophisticated, data-driven longevity interventions.
AI-driven drug discovery and aging · news_exa
AI at the forefront of age-related disease treatment
By Dr Ann Beliën (Founder and CEO of Rejuvenate Biomed) · just now
TL;DR: AI-driven automation is accelerating treatments for age-related chronic diseases.
AI is moving to the forefront of treating age-related diseases by automating high-content imaging and drug screening. These technological advancements allow for faster clinical translation of treatments for conditions like cancer and neurodegeneration. Automation at scale is becoming the new standard for longevity clinics.
AI-driven drug discovery and aging · news_exa
Deep learning and generative artificial intelligence in aging research and healthy longevity medicine
By Dominika Wilczok 1 , 2 ,
, · just now
TL;DR: Generative AI is creating new molecular structures to promote healthy longevity.
Recent advances in generative AI and deep learning are being applied to healthy longevity medicine with promising results. These models can simulate biological aging processes and generate novel molecular structures to counteract them. It represents a paradigm shift from observation to proactive biological design.
AI-driven drug discovery and aging · news_exa
AI-driven drug discovery using a context-aware hybrid model to optimize drug-target interactions | Scientific Reports
By news_exa · just now
TL;DR: Hybrid AI models improve drug precision by analyzing biological context.
A new context-aware hybrid AI model has been developed to optimize drug-target interactions with high precision. By understanding the specific biological context of a disease, the model reduces side effects and improves efficacy. This method is particularly relevant for the complex, multifaceted nature of aging.
AI-driven drug discovery and aging · news_exa
Liquid AI and Insilico Launch LFM2-2.6B-MMAI: Lightweight Model for On-Premise Drug Discovery - GeneOnline News
By Steven Chung · 1d ago
TL;DR: Liquid AI and Insilico launch a lightweight, on-premise AI model for drug discovery.
Liquid AI and Insilico Medicine have teamed up to release LFM2-2.6B-MMAI, a compact large model designed specifically for drug discovery. This lightweight tool allows pharmaceutical companies to run powerful AI simulations on-premise rather than in the cloud. It is a major win for data privacy and efficiency in the competitive race for new therapeutics.
AI-driven drug discovery and aging · news_exa
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgenc - 04.03.2026
By news_exa · 1d ago
TL;DR: KALA BIO launches strategic on-premises AI platform initiative for biotech research.
KALA BIO is pivoting toward permanent digital infrastructure by deploying a proprietary on-premises AI platform dubbed 'Researgenc.' Through a new exclusive licensing agreement, the company aims to modernize biotech research while maintaining strict control over its data. This move signals a growing trend of biotech firms building internal tech stacks to accelerate R&D.
AI-driven drug discovery and aging · news_exa
iLoF and Industry Leader Bluepharma Announce Strategic Collaboration to Deploy AI-Powered Optomics® for Faster Drug Development and to Advance the Future of Personalised Medicine
By iLoF · 1d ago
TL;DR: iLoF and Bluepharma partner to use AI-powered optics for personalized medicine.
iLoF and Bluepharma have announced a strategic partnership to integrate the AI-powered Optomics platform into drug development workflows. The collaboration focuses on using optical fingerprints and AI to streamline clinical trials and advance personalized medicine. This deal highlights how digital twins and advanced screening are becoming essential to pharma manufacturing.
AI-driven drug discovery and aging · news_exa
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
By Kyle Umipig · 1d ago
TL;DR: Annovis CEO expects a breakthrough for Alzheimer's drug this spring.
Annovis Bio's CEO is anticipating a major breakthrough this spring regarding the company's lead Alzheimer’s drug candidate. The upcoming data readouts are highly anticipated in a field that has seen recent dramatic shifts in treatment approaches. If successful, the results could provide a significant boost to the company’s valuation and patient hope.
AI-driven drug discovery and aging · news_exa
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate
By Entera Bio · 1d ago
TL;DR: Entera Bio streamlines Phase 3 protocol for oral osteoporosis drug EB613.
Entera Bio has submitted a streamlined Phase 3 protocol for its oral osteoporosis drug, EB613, aiming to shorten the primary endpoint assessment from 24 months to just 12. This move could significantly accelerate the path to market for postmenopausal women seeking non-injectable options. By focusing on bone mineral density at the hip, the company is looking for a faster regulatory win.
AI-driven drug discovery and aging · news_exa
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC
By HUTCHMED (China) Limited · 1d ago
TL;DR: HUTCHMED begins global trial for new solid tumor cancer candidate.
HUTCHMED has officially initiated a global clinical trial for HMPL-A580, an innovative candidate targeting solid tumors via the PI3K/PIKK-EGFR pathway. The study marks a significant expansion of the company's oncology pipeline into broader global markets. This trial reflects the ongoing industry rush to find more effective multi-pathway cancer inhibitors.
AI-driven drug discovery and aging · news_exa
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
By Hoth Therapeutics, Inc. · 1d ago
TL;DR: Hoth Therapeutics adopts OpenAI API to advance its orphan oncology program.
Hoth Therapeutics is integrating the OpenAI API to accelerate the development of its HT-KIT oncology program, specifically for orphan diseases. By utilizing large language models to analyze complex biological data, the company hopes to shorten the discovery timeline for rare cancers. This move underscores the growing reliance on mainstream AI tools like GPT in specialist biotech niches.
AI-driven drug discovery and aging · news_exa
Hwasun Chonnam National University Hospital will build a space medicine research platform based on t.. - MK
By SIM Heejin
edge@mk.co.kr · 1d ago
TL;DR: Hwasun Chonnam National University Hospital launches a dedicated space medicine research platform.
Hwasun Chonnam National University Hospital is set to develop a specialized research platform dedicated to space medicine. This initiative aims to explore how human health is impacted by extraterrestrial environments, leveraging cutting-edge technology. It represents a significant step for Korea's medical field as it prepares for the emerging era of space exploration.
AI-driven drug discovery and aging · news_exa
HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
By HotSpot Therapeutics · 1d ago
TL;DR: HotSpot Therapeutics reveals new preclinical data for a targeted Lupus inhibitor.
HotSpot Therapeutics showcased promising preclinical findings for its IRF5 inhibitor program at the 15th European Lupus Meeting. The data highlights the potential of using small molecules to target key drivers of autoimmune disease inflammation. This breakthrough could pave the way for more effective, targeted treatments for patients suffering from Lupus.
AI-driven drug discovery and aging · news_exa
Deep Learning and Drug Discovery for Healthy Aging | ACS Central Science
By news_exa · just now
TL;DR: Deep learning models are being optimized to discover drugs for healthy aging.
This research details how deep learning models are specifically designed to find solutions for healthy aging. By leveraging advanced neural networks, scientists can predict drug-target interactions with unprecedented accuracy. These computational tools are essential for the next generation of geroprotective medicine.
AI-driven drug discovery and aging · news_exa
Towards AI-driven longevity research: An overview
By news_exa · just now
TL;DR: An overview of how AI bridges longevity data gaps for clinical use.
An overview of AI-driven longevity research highlights its potential to revolutionize interventions in the aging process. The review focuses on how machine learning bridges the gap between massive datasets and actionable clinical trials. This transition is vital for making personalized longevity medicine a reality.
AI-driven drug discovery and aging · news_exa
Full article: The ongoing challenge of slowing ageing through drug discovery
By Rafael de Cabo · just now
TL;DR: A status report on the ongoing struggle to develop effective human geroprotectors.
Slowing the aging process remains an elusive challenge, but recent preclinical advances are providing new hope. This article reviews current geroprotectors and the ongoing struggle to translate animal successes into human treatments. Understanding the epidemiological link between aging and chronic disease is the primary focus.
AI-driven drug discovery and aging · news_exa
Contact - Observer-Reporter
By By:
KALA BIO, Inc. via
GlobeNewswire · 1d ago
TL;DR: KALA BIO expands into AI infrastructure through a new licensing agreement.
KALA BIO has finalized a licensing agreement for the 'Researgenc' platform, marking its entry into the AI infrastructure space. The strategic initiative is designed to provide the biotech industry with more robust, on-premises data solutions. This development emphasizes the industry-wide shift toward data sovereignty and secure AI deployment.